In addition, since November this company has been working on a dose especially aimed at combating the omicron variant.
The CEO of the American pharmaceutical company Moderna, Stephane Bancel, said this Monday in his speech at the Davos Forum that his company continues to work on the development of a vaccine that works against the flu and covid-19 at the same time, although he indicated which will not be ready before the end of 2023.
“It would be an annual booster dose so that people avoid having to be inoculated two or three times in winter,” explained Bancel, who admitted that it is necessary to reduce the current high frequency of booster doses to prevent people from rejecting the vaccination.
The head of one of the two firms that have developed vaccines against covid-19 with the new messenger RNA technology (the other is Pfizer-BioNTech) also stressed that since November his company has been working on a dose especially aimed at combating the omicron variant of the coronavirus, already dominant in the world.
“The laboratories will finish this work in the coming weeks and will share the results with the regulatory authorities,” the businessman said.
In this regard, the main US Government Health Adviser, Anthony Fauci, indicated in the same forum that the current situation in which booster doses are considered every time a new variant of the coronavirus emerges is not optimal. , and a universal vaccine that can serve against any evolution of SARS-CoV-2 should be attempted.